At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed May 27, 2026 at 06:30 ET
Apogee Therapeutics announced positive 16-week Phase 2 APEX Part B data for zumilokibart in moderate-to-severe atopic dermatitis, meeting primary and secondary endpoints with high statistical significance. The mid-dose achieved 65.9% EASI-75 (41.9% placebo-adjusted) and a favorable safety profile, supporting advancement into Phase 3 trials in 2H 2026. A strategic financing collaboration with Blackstone Life Sciences was also announced, expected to fund through commercialization.
- Phase 2 APEX Part B met primary endpoint: mid-dose zumilokibart achieved 65.9% EASI-75 vs 23.4% placebo (p<0.001).
- Key secondary endpoints met: IGA 0/1 46.0% vs 10.9%, EASI-90 47.4% vs 9.3%, I-NRS ≥4 50.5% vs 13.9% (all p<0.001).
- Very Low Disease Activity (vLDA) achieved in 20.6% of mid-dose patients vs 4.5% placebo (p<0.01).
- Safety profile consistent with class; conjunctivitis rate for mid-dose was 10.6% vs 20.7% for high dose.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access